CAJ | 학술논문

目的：观察贝那普利和贝尼地平联合治疗2型糖尿病肾病的临床疗效。方法将2012年1月至2013年1月中国人民解放军北京军区北戴河疗养院收治疗的90例2型糖尿病肾病患者依据随机数字表法分为三组：A组30例口服贝尼地平4 mg，B组30例口服贝那普利10 mg，C组30例口服贝尼地平4 mg和贝那普利10 mg。疗程12周，观察三组治疗前后血压、血糖和肾功能的变化以及不良反应情况。结果治疗12周后，三组患者收缩压、舒张压、24 h尿蛋白均较治疗前下降（ P＜0．01）；三组治疗前后血尿素氮、血肌酐、肌酐清除率、血清电解质（K ＋）和空腹血糖比较差异均无统计学意义（P＞0．05）。三组不良反应发生率比较差异无统计学意义（P＞0．05）。结论贝那普利、贝尼地平长期单独治疗均可有效降低血压和减少尿蛋白，两者联用在治疗2型糖尿病肾病的治疗上可增加疗效并减少不良反应。
목적：관찰패나보리화패니지평연합치료2형당뇨병신병적림상료효。방법장2012년1월지2013년1월중국인민해방군북경군구북대하요양원수치료적90례2형당뇨병신병환자의거수궤수자표법분위삼조：A조30례구복패니지평4 mg，B조30례구복패나보리10 mg，C조30례구복패니지평4 mg화패나보리10 mg。료정12주，관찰삼조치료전후혈압、혈당화신공능적변화이급불량반응정황。결과치료12주후，삼조환자수축압、서장압、24 h뇨단백균교치료전하강（ P＜0．01）；삼조치료전후혈뇨소담、혈기항、기항청제솔、혈청전해질（K ＋）화공복혈당비교차이균무통계학의의（P＞0．05）。삼조불량반응발생솔비교차이무통계학의의（P＞0．05）。결론패나보리、패니지평장기단독치료균가유효강저혈압화감소뇨단백，량자련용재치료2형당뇨병신병적치료상가증가료효병감소불량반응。
Objective To observe the clinical efficacy of combined therapy of benazepril and benidipine for patients with type 2 diabetic nephropathy.Methods A total of 90 patients with type 2 diabetic nephropa-thy admitted in PLA Beijing Military Region Beidaihe Sanatorium from Jan .2012 to Jan.2013 were randomly divided into three groups:group A(patients were given 4 mg of Benidipine), group B(patients were given 10 mg of benazepril),and group C(patients were given 4 mg of benidipine and 10 mg of benazepril).After an average of 12 weeks follow-up,blood pressure,blood sugar level,kidney function,and adverse reactions of the three groups were observed and studied.Results After 12 weeks of treatment, systolic pressure, diastolic pressure,24-h urinary protein of the three groups all decreased(P<0.01).In the three groups before and after treatment,levels of blood urea nitrogen, serum creatinine, creatinine clearance rate, serum electrolyte ( K +) and fasting blood glucose had no statistically significant differences ( P >0 .05 ) .The incidence of adverse reactions of the three groups had no statistically significant difference (P >0.05).Conclusion Long-term application of single benazepril,or benidipine can effectively lower the blood pressure and reduce urinary protein;while the combined therapy of the two drugs can improve the efficacy of the treatment for type 2 diabetic nephropathy and reduce adverse reactions.